- Merck (MRK) is set to collaborate with GlaxoSmithKline (GSK) to test a MK-3475 (that's the PD-1 inhibitor)/ pazopanib combo in advanced renal cell carcinoma.
- MRK senior VP Iain Dukes says "collaborations like this are central to MRK's strategy to evaluate the potential of MK-3475 for the treatment of cancer."
- The companies have initiated a Phase 1/2 trial in treatment naïve patients. (PR)
Merck, Glaxo to test combo treatment in renal cell carcinoma
Dec 18 2013, 07:56 ET